Ocrevus

Approved Indications

Ocrevus is used to treat adults with various forms of multiple sclerosis (MS). It is specifically indicated for:

• Relapsing forms of MS: This category includes clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. For these patients, the medication is used to reduce the frequency of clinical relapses and slow the progression of physical disability.
• Primary progressive MS (PPMS): Ocrevus is the first therapy approved to treat this form of the disease, which involves a steady progression of symptoms without early relapses or remissions.

Healthcare providers prescribe Ocrevus as a disease-modifying therapy. It is intended to manage the underlying disease process rather than just treating individual symptoms of an MS attack.

Targeting B Cells

Ocrevus (ocrelizumab) is designed to target a specific type of white blood cell called a B cell. In people with multiple sclerosis (MS), the immune system mistakenly attacks the protective covering of nerves, known as the myelin sheath. B cells are believed to play a key role in this process by triggering inflammation and damage to the central nervous system.

Mechanism of Action

The medication works through a process of immune cell depletion:

• Binding: Ocrevus is a monoclonal antibody that attaches to a protein called CD20 found on the surface of certain B cells.
• Depletion: Once attached, the medication helps the immune system identify and destroy these specific B cells.
• Protection: By reducing the number of these B cells in the bloodstream, Ocrevus helps lower the overall immune response that leads to MS relapses and the progression of disability.

While Ocrevus reduces the number of CD20-positive B cells, it does not target all immune cells. Other types of B cells and T cells remain to help the body fight infections, though the overall immune system may still be weakened during treatment. The exact way Ocrevus exerts its therapeutic effects in MS is not fully understood, but it is primarily attributed to this reduction in B cell activity.

Common Side Effects

The most frequently reported side effects of Ocrevus involve reactions during the infusion or infections. Common symptoms include:

• Upper respiratory tract infections (such as the common cold)
• Infusion-related reactions
• Skin infections
• Lower respiratory tract infections

Infusion Reactions

Infusion reactions are most likely to occur during the first dose. Healthcare providers typically monitor patients for at least one hour after the infusion ends. Symptoms can include:

• Itchy skin, rash, or hives
• Redness or flushing of the skin
• Headache, dizziness, or tiredness
• Throat irritation or cough
• Nausea or fast heartbeat
• Fever or chills

Serious Side Effects

Some side effects require immediate medical attention. These may include:

• Serious Infections: Ocrevus affects the immune system, which may increase the risk of life-threatening infections.
• Progressive Multifocal Leukoencephalopathy (PML): A rare but serious brain infection caused by the JC virus.
• Hepatitis B Reactivation: If you have had Hepatitis B in the past, the virus could become active again.
• Risk of Cancer: There may be an increased risk of certain malignancies, including breast cancer. Regular cancer screenings are recommended.

Infusion Reactions

Infusion reactions are common with Ocrevus and can sometimes be life-threatening. These reactions typically occur during the infusion or within 24 hours afterward. Symptoms may include:

• Itchy skin, rash, or hives
• Coughing, wheezing, or shortness of breath
• Throat irritation or swelling
• Fever, chills, or fatigue
• Fast heartbeat or dizziness

Healthcare providers usually monitor patients for at least one hour after the infusion is complete to manage any immediate reactions.

Risk of Infections

Ocrevus affects the immune system, which may increase the risk of developing infections or worsening existing ones. Serious infections can occur, including:

• Progressive Multifocal Leukoencephalopathy (PML): A rare but serious brain infection caused by the JC virus that can lead to disability or death.
• Hepatitis B Reactivation: If a person has had hepatitis B in the past, the virus could become active again during or after treatment. Screening for hepatitis B is required before the first dose.
• Herpes Infections: There is an increased risk of shingles, cold sores, and other herpes-related infections.
• Respiratory and Skin Infections: Common infections include those affecting the upper respiratory tract and the skin.

Vaccinations

Live or live-attenuated vaccines should not be administered while taking Ocrevus. It is recommended that all necessary vaccinations be completed at least several weeks before starting treatment. The safety of receiving vaccines shortly after treatment is not fully established, as the drug may reduce the body's immune response to the vaccine.

Malignancy Risk

An increased risk of developing certain types of cancer, including breast cancer, has been observed in clinical trials. Routine cancer screenings are generally recommended according to standard healthcare guidelines while using this medication.

Contraindications

Ocrevus should not be used by individuals with an active hepatitis B infection. It is also contraindicated for those who have had a life-threatening allergic reaction to ocrelizumab or any of its ingredients in the past.

Pregnancy

Ocrevus may cause harm to an unborn baby. Because the medication works by depleting certain immune cells (B cells), it could potentially affect the development of the immune system in a fetus. There is currently limited data on the safety of Ocrevus in pregnant women.

Important considerations for those who can become pregnant include:

• Contraception: Use effective birth control during treatment and for at least 6 months after the final dose of Ocrevus.
• Planning: If you are planning to become pregnant, discuss the timing of your treatment with your healthcare provider.
• Notification: Inform your doctor immediately if you become pregnant while receiving this medication or within 6 months of your last infusion.

Breastfeeding

It is not known if Ocrevus passes into human breast milk or if it could affect a nursing infant. Because many medications are excreted in human milk, there is a potential for serious adverse reactions in infants. You should discuss the benefits and risks of breastfeeding with your healthcare provider to determine the best approach while receiving treatment.

Available Forms

Ocrevus is supplied as a liquid solution for intravenous infusion. It is a clear to slightly opalescent, colorless to pale brown liquid.

The medication is provided in vials. It is diluted by a healthcare professional before being administered into a vein.

FDA Approval and Indications

Ocrevus (ocrelizumab) is approved by the FDA for the treatment of adults with relapsing forms of multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS). For relapsing forms, its indication includes clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease.

Regulatory Requirements and Safety Monitoring

The FDA requires specific screening and monitoring protocols for patients prescribed Ocrevus:

• Hepatitis B Screening: Healthcare providers must screen patients for Hepatitis B virus (HBV) infection before the first dose. The medication is contraindicated in patients with active HBV.
• Infusion Monitoring: Because of the risk of infusion-related reactions, the drug must be administered by a healthcare professional prepared to manage severe allergic or skin reactions.
• Infection Risk: Regulatory information highlights the risk of serious infections. While rare, there is a potential risk for progressive multifocal leukoencephalopathy (PML), a viral brain infection. Patients must be monitored for any new or worsening neurological symptoms.

Vaccination Status

Regulatory guidelines recommend that all required immunizations be completed at least six weeks prior to starting Ocrevus. The use of live-attenuated or live vaccines is not recommended during treatment and until B-cell levels have recovered.

Factors Influencing Cost

Several factors determine the final out-of-pocket cost for Ocrevus treatment, including:

• Insurance Coverage: Most private insurance plans and Medicare cover Ocrevus for its approved uses, though they often require prior authorization before treatment begins.
• Treatment Setting: Receiving the infusion at a hospital-based outpatient center may cost more than receiving it at a standalone infusion clinic or through a home infusion service.
• Deductibles and Copays: Individual plan details, such as annual deductibles and coinsurance percentages, will impact how much a patient pays for each dose.

Additional Expenses

The total cost of a treatment session involves more than just the drug itself. Patients may also be billed for:

• Nursing care and monitoring during the infusion.
• Facility fees for the use of the infusion suite.
• Pre-medications, such as corticosteroids or antihistamines, given to reduce the risk of infusion reactions.

Financial Assistance

The manufacturer often provides support programs to help eligible patients manage costs. These may include copay cards for those with commercial insurance or assistance for patients who are uninsured or underinsured. Patients are encouraged to speak with their healthcare provider or insurance coordinator to explore these options before starting therapy.